High-density lipoprotein cholesterol as a therapeutic target to reduce cardiovascular events

American Heart Journal

Volumn 147, Issue 6, 2004, Pages 939-941

  Fonarow, Gregg C ^a   Watson, Karol E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; ETC 216; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PHENYTOIN; PROSTACYCLIN; STATIN; VERY LOW DENSITY LIPOPROTEIN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; DISEASE COURSE; EDITORIAL; GENE MUTATION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; LIPID METABOLISM; LIPID OXIDATION; MORTALITY; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RISK REDUCTION; STATISTICAL SIGNIFICANCE;

ADULT; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN A-I; CHOLESTEROL, HDL; CORONARY ARTERIOSCLEROSIS; FEMALE; HUMANS; MALE;

EID: 3042853375     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2004.01.014     Document Type: Editorial

References (18)

1. LaRosa J.C., He J., Vupputuri S. Effect of statins on risk of coronary disease a meta-analysis of randomized controlled trials. JAMA. 282:1999;2340-2346
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497
3. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals a randomised placebo-controlled trial. Lancet. 360:2002;7-22
4. Wood D., De Backer G., Faergeman O., et al. Prevention of coronary heart disease in clinical practice recommendations of the second joint task force of European and other societies on coronary prevention. Eur Heart J. 19:1998;1434-1503
5. Grundy S.M. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation. 106:2002;2526-2529
6. Castelli W.P., Garrison R.J., Wilson P.W., et al. Incidence of coronary heart disease and lipoprotein cholesterol levels the Framingham Study. JAMA. 256:1986;2835-2838
7. Wilson P.W., Anderson K.M., Castelli W.P. Twelve-year incidence of coronary heart disease in middle-age adults during the era of hypertensive therapy the Framingham offspring study. Am J Med. 90:1991;11-16
8. Sharrett A.R., Patsch W., Sorlie P.D., et al. Associations of lipoprotein cholesterols, apolipoproteins A-I and B, and triglycerides with carotid atherosclerosis and coronary heart disease the Atherosclerosis Risk in Communities (ARIC) study. Arterioscler Thromb. 14:1994;1098-1104
9. Maron D.J. The epidemiology of low levels of high-density lipoprotein cholesterol in patients with and without coronary artery disease. Am J Cardiol. 86:2000;11-14L
10. Shah P.K., Kaul S., Nilsson J., et al. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins an idea whose time for testing is coming, part I. Circulation. 104:2001;2376-2383
11. Navab M., Berliner J.A., Subbanagounder G., et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol. 21:2001;481-488
12. Plump A.S., Scott C.J., Breslow J.L. Human apolipoprotein A-I gene expression increases high-density lipoprotein and suppresses atherosclerosis in the apolipoprotein E- deficient mouse. Proc Natl Acad Sci U S A. 91:1994;9607-9611
13. De Geest B., Zhao Z., Collen D., et al. Effects of adenovirus-mediated human apo A-I gene transfer on neointima formation after endothelial denudation in apo E-deficient mice. Circulation. 96:1997;4349-4356
14. Navab M., Anantharamaiah G.M., Hama S., et al. Oral administration of an Apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation. 105:2002;290-292
15. Dean BB, Borenstein JE, Henning JM, et al. Can change in high-density lipoprotein cholesterol levels reduce cardiovascular risk? Am Heart J 2004;147:966-76
16. Pasternak R.C. The ALLHAT lipid lowering trial - less is less. JAMA. 288:2002;3042-3044
17. Shah P.K., Kaul S., Nilsson J., et al. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins an idea whose time for testing is coming, part II. Circulation. 104:2001;2498-2502
18. Nissen S.E., Tsunoda T., Tuzcu E.M., et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes a randomized controlled trial. JAMA. 290:2003;2292-2300